SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Vonderheid-Guth, B., Todorova, A., Wedekind, W. and Dimpfel, W. (2000) Evidence for Neuronal Dysfunction in Mi- graine: Concurrence between Specific qEEG Findings and Clinical Drug Response—A Retrospective Analysis. European Journal of Medical Research, 5, 473-483.

has been cited by the following article:

  • TITLE: Quantitative EEG Changes in Patients with Parkinson’s Disease during Therapy with Rasagiline

    AUTHORS: Wilfried Dimpfel, Christian Oehlwein, Josef Anton Hoffmann, Thomas Müller

    KEYWORDS: Rasagiline, Selegiline, Quantitative EEG, CATEEM®, Parkinson’s Disease, Cognition

    JOURNAL NAME: Advances in Parkinson's Disease, Vol.3 No.3, August 28, 2014

    ABSTRACT: It has been suggested that in patients with Parkinson’s disease (PD) metabolism of the MAO-B inhibitor selegiline to methamphetamine may contribute and/or exacerbate sleep problems, possibly leading to deficits of cognition. This open-label exploratory study included 30 PD patients currently being treated with selegiline (7.5 mg/day) and complaining of sleep disturbances. The aim of the study was to determine whether switching from selegiline to another MAO-B inhibitor without amphetamine-like metabolites, namely rasagiline, would improve sleep behaviour and cognitive function in PD patients. Pathologic aberrations as determined by comparison of the frequency pattern of patients to a database consisting of healthy subjects revealed an approximation of electric brain activity to normality. For verification of efficacy, a combination of questionnaires, quantitative source density EEG recording with CATEEMò and performance of two psychometric tasks (d2-test of attention and reading) during the EEG recording were done on the last day of selegiline treatment (7.5 mg/day) as well as 2 and 4 months later, during which the patients were treated with rasagiline (1 mg/day). In addition, performance of the mental tasks revealed a statistically significant (p